UK markets closed

Acacia Pharma Group plc (0PNT.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
2.3200+0.1450 (+6.67%)
At close: 5:43PM BST

Acacia Pharma Group plc

The Officers’ Mess
Royston Road Duxford
Cambridge CB22 4QH
United Kingdom
44 1223 919760

Full-time employees72

Key executives

NameTitlePayExercisedYear born
Mr. Michael BolinderCEO & Director1.13MN/AN/A
Mr. Gary G. GemignaniChief Financial OfficerN/AN/A1965
Dr. Gabriel FoxChief Medical OfficerN/AN/AN/A
Dr. Ian WalkerHead of Project LeadershipN/AN/AN/A
Anne-Marie ElsleyCompany Sec.N/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Acacia Pharma Group plc, a hospital pharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, other invasive procedures, or cancer chemotherapy treatments in the United States and internationally. The company's lead product is BARHEMSYS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also include BYFAVO, an ultra-short-acting and reversible intravenous sedative benzodiazepine for the use in invasive medical procedures, such as bronchoscopies and colonoscopies; and APD403, an intravenous and oral amisulpride that has completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting. The company's products are primarily serves anesthesiologists and oncologists. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.

Corporate governance

Acacia Pharma Group plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.